Cargando…

Alpha-ketoglutarate supplementation and BiologicaL agE in middle-aged adults (ABLE)—intervention study protocol

Targeting molecular processes of aging will enable people to live healthier and longer lives by preventing age-related diseases. Geroprotectors are compounds with the potential to increase healthspan and lifespan. Even though many of them have been tested in animal models, the translation to humans...

Descripción completa

Detalles Bibliográficos
Autores principales: Sandalova, Elena, Goh, Jorming, Lim, Zi Xiang, Lim, Zhi Meng, Barardo, Diogo, Dorajoo, Rajkumar, Kennedy, Brian K., Maier, Andrea B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643463/
https://www.ncbi.nlm.nih.gov/pubmed/37217632
http://dx.doi.org/10.1007/s11357-023-00813-6
_version_ 1785147120371630080
author Sandalova, Elena
Goh, Jorming
Lim, Zi Xiang
Lim, Zhi Meng
Barardo, Diogo
Dorajoo, Rajkumar
Kennedy, Brian K.
Maier, Andrea B.
author_facet Sandalova, Elena
Goh, Jorming
Lim, Zi Xiang
Lim, Zhi Meng
Barardo, Diogo
Dorajoo, Rajkumar
Kennedy, Brian K.
Maier, Andrea B.
author_sort Sandalova, Elena
collection PubMed
description Targeting molecular processes of aging will enable people to live healthier and longer lives by preventing age-related diseases. Geroprotectors are compounds with the potential to increase healthspan and lifespan. Even though many of them have been tested in animal models, the translation to humans is limited. Alpha-Ketoglutarate (AKG) has been studied widely in model animals, but there are few studies testing its geroprotective properties in humans. ABLE is a double blinded placebo-controlled randomized trial (RCT) of 1 g sustained release Ca-AKG versus placebo for 6 months of intervention and 3 months follow up including 120 40–60-year-old healthy individuals with a higher DNA methylation age compared to their chronological age. The primary outcome is the decrease in DNA methylation age from baseline to the end of the intervention. A total of 120 participants will be randomized to receive either sustained release Ca-AKG or placebo. Secondary outcomes include changes in the inflammatory and metabolic parameters in blood, handgrip strength and leg extension strength, arterial stiffness, skin autofluorescence, and aerobic capacity from baseline to 3 months, 6 months, and 9 months. This study will recruit middle-aged participants with an older DNA methylation age compared to their chronological age, and test whether supplementation with Ca-AKG can reduce DNA methylation age. This study is unique in its inclusion of biologically older participants. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11357-023-00813-6.
format Online
Article
Text
id pubmed-10643463
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-106434632023-11-15 Alpha-ketoglutarate supplementation and BiologicaL agE in middle-aged adults (ABLE)—intervention study protocol Sandalova, Elena Goh, Jorming Lim, Zi Xiang Lim, Zhi Meng Barardo, Diogo Dorajoo, Rajkumar Kennedy, Brian K. Maier, Andrea B. GeroScience Original Article Targeting molecular processes of aging will enable people to live healthier and longer lives by preventing age-related diseases. Geroprotectors are compounds with the potential to increase healthspan and lifespan. Even though many of them have been tested in animal models, the translation to humans is limited. Alpha-Ketoglutarate (AKG) has been studied widely in model animals, but there are few studies testing its geroprotective properties in humans. ABLE is a double blinded placebo-controlled randomized trial (RCT) of 1 g sustained release Ca-AKG versus placebo for 6 months of intervention and 3 months follow up including 120 40–60-year-old healthy individuals with a higher DNA methylation age compared to their chronological age. The primary outcome is the decrease in DNA methylation age from baseline to the end of the intervention. A total of 120 participants will be randomized to receive either sustained release Ca-AKG or placebo. Secondary outcomes include changes in the inflammatory and metabolic parameters in blood, handgrip strength and leg extension strength, arterial stiffness, skin autofluorescence, and aerobic capacity from baseline to 3 months, 6 months, and 9 months. This study will recruit middle-aged participants with an older DNA methylation age compared to their chronological age, and test whether supplementation with Ca-AKG can reduce DNA methylation age. This study is unique in its inclusion of biologically older participants. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11357-023-00813-6. Springer International Publishing 2023-05-23 /pmc/articles/PMC10643463/ /pubmed/37217632 http://dx.doi.org/10.1007/s11357-023-00813-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Sandalova, Elena
Goh, Jorming
Lim, Zi Xiang
Lim, Zhi Meng
Barardo, Diogo
Dorajoo, Rajkumar
Kennedy, Brian K.
Maier, Andrea B.
Alpha-ketoglutarate supplementation and BiologicaL agE in middle-aged adults (ABLE)—intervention study protocol
title Alpha-ketoglutarate supplementation and BiologicaL agE in middle-aged adults (ABLE)—intervention study protocol
title_full Alpha-ketoglutarate supplementation and BiologicaL agE in middle-aged adults (ABLE)—intervention study protocol
title_fullStr Alpha-ketoglutarate supplementation and BiologicaL agE in middle-aged adults (ABLE)—intervention study protocol
title_full_unstemmed Alpha-ketoglutarate supplementation and BiologicaL agE in middle-aged adults (ABLE)—intervention study protocol
title_short Alpha-ketoglutarate supplementation and BiologicaL agE in middle-aged adults (ABLE)—intervention study protocol
title_sort alpha-ketoglutarate supplementation and biological age in middle-aged adults (able)—intervention study protocol
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643463/
https://www.ncbi.nlm.nih.gov/pubmed/37217632
http://dx.doi.org/10.1007/s11357-023-00813-6
work_keys_str_mv AT sandalovaelena alphaketoglutaratesupplementationandbiologicalageinmiddleagedadultsableinterventionstudyprotocol
AT gohjorming alphaketoglutaratesupplementationandbiologicalageinmiddleagedadultsableinterventionstudyprotocol
AT limzixiang alphaketoglutaratesupplementationandbiologicalageinmiddleagedadultsableinterventionstudyprotocol
AT limzhimeng alphaketoglutaratesupplementationandbiologicalageinmiddleagedadultsableinterventionstudyprotocol
AT barardodiogo alphaketoglutaratesupplementationandbiologicalageinmiddleagedadultsableinterventionstudyprotocol
AT dorajoorajkumar alphaketoglutaratesupplementationandbiologicalageinmiddleagedadultsableinterventionstudyprotocol
AT kennedybriank alphaketoglutaratesupplementationandbiologicalageinmiddleagedadultsableinterventionstudyprotocol
AT maierandreab alphaketoglutaratesupplementationandbiologicalageinmiddleagedadultsableinterventionstudyprotocol